Investors
Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Found 316 Results
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
February 28, 2024
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
February 15, 2024
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
February 9, 2024
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
February 5, 2024
Palatin Announces Closing of $10 Million Registered Direct Offering
February 1, 2024
Palatin Announces $10 Million Registered Direct Offering
January 30, 2024
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
January 8, 2024
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
December 20, 2023
Page 3 of 32